Pharmaceutical Preparations

Pharmaceutical Preparations (SIC 2834) covers companies formulating, manufacturing, and marketing prescription drugs, over-the-counter remedies, vaccines, biologics, and specialty therapies for hospitals, clinics, pharmacies, PBMs, and increasingly direct-to-consumer channels. Customers span health systems, insurers, physicians, and patients managing chronic and acute conditions. The sector operates under FDA and EMA approvals, GMP compliance, pharmacovigilance duties, patent cliffs, pricing scrutiny, and evolving rules on digital promotion and AI-driven clinical decision support. Key risks include clinical trial setbacks, supply chain fragility for active ingredients, reimbursement pressure, and heightened cybersecurity expectations around patient data. In 2024-2025, firms are accelerating mRNA platforms, cell and gene therapies, GLP-1 and metabolic drugs, antibody-drug conjugates, and digital companions, while optimizing portfolios through licensing and M&A to offset patent expirations. For timely disclosures, pipeline updates, and pricing actions, view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last fetched 11/23/2025